Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Death domain-associated protein 6 (DAXX) is a multifunctional nuclear and cytoplasmic protein that acts principally as a histone chaperone specific for the replication-independent histone variant H3.3, regulating chromatin assembly and structure, gene transcription, and apoptosis[1][2][3][4]. DAXX interacts with ATRX to mediate H3.3 deposition at pericentromeric heterochromatin and telomeres, thereby affecting genome stability and telomere maintenance[1][2][3][4]. In the nucleus, DAXX also functions as a potent transcriptional corepressor through interaction with sumoylated transcription factors and chromatin proteins and localizes to promyelocytic leukemia nuclear bodies (PML-NBs)[1][3]. In the cytoplasm, DAXX was initially identified as a Fas-interacting protein that promotes apoptosis through the JNK pathway but can also mediate anti-apoptotic effects depending on context, such as its subcellular localization and binding partners[3][5]. Dysregulation, mislocalization, or overexpression of DAXX is implicated in multiple cancer types and may be linked to disease progression, prognosis, and potential therapeutic targeting[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Death domain-associated protein 6 (DAXX).